Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimebon + omeprazole
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dimebon + omeprazole is a combination of two small molecule drugs. Dimebon (also known as dimebolin or Dimebonum) is an antihistamine that was investigated for neurodegenerative diseases such as Alzheimer's disease and Huntington's disease but development was discontinued after negative clinical trial results. Its mechanism of action is not fully understood but may involve mitochondrial stabilization and weak NMDA receptor antagonism. Omeprazole is a proton pump inhibitor (PPI) used to treat gastric acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and erosive esophagitis. It works by selectively inhibiting the H+/K+ ATPase enzyme in gastric parietal cells to reduce stomach acid production[1][2][3][5][6]. Omeprazole has been marketed under several brand names including Prilosec and Zegerid. There are no approved indications for the fixed combination of these two drugs; however, they have been studied together in pharmacokinetic interaction studies[4].
- Brand names
- PriLOSECPriLOSEC OTCZegeridFIRST Omeprazole
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)ATP4A (Potassium–transporting ATPase alpha chain 1)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Dimebon + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dimebon + omeprazole.